




Healthcare Industry News: HSMN NewsFeed
News Release - June 4, 2020
MedHub AutocathFFR Awarded AMAR Certification, Israel's Medical Device Regulatory Approval
AutocathFFR, the company's first commercial product, is a transformative cardiac diagnosis system.TEL AVIV, Israel, June 4, 2020 -- (Healthcare Sales & Marketing Network) -- MedHub Ltd., a medical technology company focused on developing and commercializing AI powered medical solutions that aid in the diagnosis of cardiac disease, announced that is has gained AMAR approval for its AutocathFFR system. AutocathFFR is an automated, image based cardiac diagnosis system that provides non-invasive FFR measurements. It is designed for use by interventional cardiologists to improve their decision making in hospital, ambulatory clinic and home settings.
Mr. Baruch El added that in light of the AMAR approval, "MedHub will begin with its plan to provide AutocathFFR to several Israeli hospitals, who will serve as early adopters of our technology."
About AutocathFFR
AutocathFFR was designed to deliver both ease of use and accessibility. With AutocathFFR, Cardiologists simply run the software during the initial diagnostic angiogram, and automatically receive an FFR score for each stenosis. With this, AutocathFFR eliminates the need for additional, costly invasive procedures that are in use today for quantifying FFR measurements, and to help improve quality of care.
AutoCathFFR benefits
- Shortens procedure times – achieved through instant FFR calculations, using image-based techniques, during initial diagnostic catheterization.
- Saves costs of further invasive diagnostic procedure.
- Saves expenditure on many unnecessary procedures.
- Reduces radiation exposure for physicians and patients alike.
Source: MedHub
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.